IL-2 Receptor Antagonist (Basiliximab) Is Associated with Rapid Fibrosis Progression in Patients with Recurrent Hepatitis C after Liver Transplantation
Background: Recurrence of hepatitis C virus (HCV) infection following orthotopic liver transplantation (OLT) is universal. There is paucity of data on the safety and efficacy of interleukin (IL)-2 receptor antagonist (IL-2RA) when added to the standard immunosuppression regimen in OLT recipients wit...
Main Authors: | Ibrahim A. Hanouneh, Nizar N. Zein, Rocio Lopez, Lisa Yerian, John Fung, Bijan Eghtesad |
---|---|
Format: | Article |
Language: | English |
Published: |
Shiraz University of Medical Sciences
2010-01-01
|
Series: | International Journal of Organ Transplantation Medicine |
Subjects: | |
Online Access: | http://home.sums.ac.ir/~habibzaf/ojs/index.php/IJOTM/article/view/3/17 |
Similar Items
-
Sofosbuvir and Simeprevir for the Treatment of Recurrent Hepatitis C with Fibrosing Cholestatic Hepatitis after Liver Transplantation
by: D Issa, et al.
Published: (2016-01-01) -
Efficacy and Safety of Emricasan in Liver Cirrhosis and/or Fibrosis
by: Li-ya Mu, et al.
Published: (2021-06-01) -
Overview of Serum Interleukin-18 (IL-18) Levels in Liver Cirrhosis Patients and Their Correlation to Hepatic Encephalopathy
by: Anton Komala, et al.
Published: (2018-08-01) -
Recurrence of Disease Following Liver Transplantation: Nonalcoholic Steatohepatitis vs Hepatitis C Virus Infection
by: A Hanouneh, et al.
Published: (2011-04-01) -
Management Strategies for Liver Fibrosis
by: Alejandra Altamirano-Barrera, et al.
Published: (2017-01-01)